{
    "nctId": "NCT05732051",
    "briefTitle": "Nicotinamide Riboside and Prevention of Cancer Therapy Related Cardiac Dysfunction in Breast Cancer Patients",
    "officialTitle": "Effect of Nicotinamide Riboside on Myocardial and Skeletal Muscle Injury and Function in Patients With Metastatic Breast Cancer Receiving Anthracyclines",
    "overallStatus": "RECRUITING",
    "conditions": "Breast Cancer, Metastatic Breast Cancer, Cancer Therapy-Related Cardiac Dysfunction, Cardiotoxicity, Heart Failure",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "PREVENTION",
    "enrollmentCount": 60,
    "primaryOutcomeMeasure": "Whether the administration of nicotinamide riboside can prevent the reduction in left ventricular systolic function measured by cardiovascular magnetic resonance (CMR), compared to placebo.",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Women with metastatic breast cancer (stage IV breast cancer) scheduled for anthracycline-containing chemotherapy\n* Eastern Cooperative Oncology Group performance status 0-2\n\nExclusion Criteria\n\n* Age \\<18 years\n* Acute myocardial infarction within the last three months\n* Participation in another pharmaceutical clinical trial of an investigational medicinal product (IMP) less than 4 weeks prior to inclusion or use of other investigational drugs within 5 half-lives of enrollment, whichever is longer\n* Conditions that would affect the participants to comply with the study protocol as psychiatric or mental disorders, alcohol abuse or other substance abuse, suspected poor drug compliance, language barriers\n* Life expectancy \\< 6 months\n* Known allergy to any of the components in the Nicotinamide Riboside (Niagen\u00ae) tablet\n* Contraindications or inability to undergo CMR examination",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}